Impact of jak inhibitors in pediatric patients with stat1 gain of function (gof) mutations—10 children and review of the literature

HIGHLIGHTS

• who: Angela Deyà-Martínez from the (UNIVERSITY) have published the article: Impact of JAK Inhibitors in Pediatric Patients with STAT1 Gain of Function (GOF) Mutations—10 Children and Review of the Literature, in the Journal: (JOURNAL)
• what: The main reasons to start JAK inhibition were immune dysregulation (10/10), manifested as oral aphthae, keratitis, enteropathy and autoimmune hepatitis, followed by uncontrolled CMC (6/10). Although specific information was not available for all previously published cases the main reason to start treatment were autoimmune complications. The study provides a detailed description of the clinical experience . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.